Top 5 Generics Companies 2025
As healthcare systems grapple with rising costs and the need for broader access to treatment, off-patent medicines have taken on increasing importance. With budgets under pressure and blockbuster drugs losing…
Switzerland’s healthcare system is at a crossroads. Although still one of the world’s bastions of biopharmaceutical innovation, the country’s domestic healthcare environment is under increasing pressure from rising costs, mounting drug shortages, and a regulatory environment that is slow to…
As healthcare systems grapple with rising costs and the need for broader access to treatment, off-patent medicines have taken on increasing importance. With budgets under pressure and blockbuster drugs losing…
John Murphy, III, president & CEO of the Association for Accessible Medicines (AAM) lays out a stark warning: the very medicines that keep the US healthcare system affordable and functioning…
Amidst the hype of Saudi Arabia’s embrace of innovative therapies and technologies, the concepts of access and affordability can often be forgotten. However, the Saudi government remains the dominant healthcare…
Will Hsu leads Sandoz operations across Taiwan, Hong Kong, and Macao, managing a portfolio spanning both generics and biosimilars in markets characterised by universal healthcare and significant budget constraints. With nearly 12 years at Sandoz, including three years in his current regional role, Hsu oversees strategic initiatives to increase biosimilar adoption in Taiwan from the current 12 percent penetration toward…
Tanya Carro details Duchesnay Pharmaceutical Group’s organic expansion from its women’s health core into rare diseases and generics. Operating across three geographic pillars, the privately held firm leverages Canadian pricing…
Eight years after establishing its Swiss affiliate as a one-man operation, Accord Healthcare has built a strong position in one of Europe’s most competitive markets, with a focused strategy in…
Mexico has become a major player in global manufacturing, attracting companies looking to bring supply chains closer to North American markets, but home-grown pharma companies are also capitalizing on the…
With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals –…
Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises? A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the…
As home to much of Europe’s innovative medicine output and as one of its wealthiest nations per capita, Switzerland has not traditionally been a generic-friendly market. Generics prices are relatively…
Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche…
For over two decades, Europe’s pharmaceutical manufacturing footprint has steadily shifted offshore towards countries like China and India, driven by the pursuit of lower costs and operational efficiencies. However, the…
See our Cookie Privacy Policy Here
